Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
40.31
-0.14 (-0.35%)
Nov 3, 2026, 9:36 AM EST - Market open
Novo Nordisk Employees
Novo Nordisk had 66,700 employees as of June 30, 2026. The number of employees decreased by 11,687 or 14.91% compared to the same quarter last year.
Employees
66,700
Change (1Y)
-11,687
Growth (1Y)
-14.91%
Revenue / Employee
$754,734
Profits / Employee
$266,774
Market Cap
178.11B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 66,700 | -11,687 | -14.91% |
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVO News
- 1 day ago - Novo Nordisk warns on Irish access to obesity drug after US pricing deal - Independent Ireland
- 2 days ago - Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? - The Motley Fool
- 4 days ago - Novo Has Big Plans for 2030. Should You Buy the Stock Now? - The Motley Fool
- 5 days ago - Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial - BNN Bloomberg
- 5 days ago - Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly - TipRanks
- 6 days ago - Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial - Reuters
- 6 days ago - Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
- 7 days ago - NVO Stock Is Trading Near Its 52-Week Low. Here’s Why That Number Tells Only Part of the Story. - ABC Money